Press Release: European Medicines Agency recommends approval of first-in-class treatment for metastatic or unresectable melanoma

Author (Corporate)
Series Title
Series Details EMA/CHMP/975685/2011 (16.12.11)
Publication Date 16/12/2011
Content Type

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), in December 2011, recommended the granting of a marketing authorisation for a novel protein-kinase inhibitor to treat patients suffering from metastatic or unresectable melanoma with BRAF V600 mutations.
Source Link http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2011/12/news_detail_001412.jsp&mid=WC0b01ac058004d5c1&murl=menus/news_and_events/news_and_events.jsp
Related Links
EMA: Press Release: EMA/CHMP/975685/2011 (16.12.11) http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2011/12/WC500119378.pdf
EMA: Press Release: EMA/385990/2013 (28.06.13) http://www.emea.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/06/news_detail_001836.jsp&mid=WC0b01ac058004d5c1
Subject Categories
Countries / Regions